S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
NASDAQ:AXGN

AxoGen (AXGN) Stock Price, News & Analysis

$7.77
+0.22 (+2.91%)
(As of 03/27/2024 ET)
Today's Range
$7.56
$7.80
50-Day Range
$7.35
$10.69
52-Week Range
$3.45
$10.83
Volume
296,087 shs
Average Volume
372,085 shs
Market Capitalization
$335.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

AxoGen MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
37.3% Upside
$10.67 Price Target
Short Interest
Bearish
4.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of AxoGen in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$928,054 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.46) to ($0.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.27 out of 5 stars

Medical Sector

540th out of 939 stocks

Electromedical Equipment Industry

7th out of 20 stocks

AXGN stock logo

About AxoGen Stock (NASDAQ:AXGN)

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

AXGN Stock Price History

AXGN Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
AxoGen Full Year 2023 Earnings: Beats Expectations
Axogen Inc (AXGN) Earnings Dates & Reports
AxoGen Q4 2023 Earnings Preview
American Well Corporation (AMWL)
Axogen Stock (NASDAQ:AXGN), Short Interest Report
AXGN Mar 2024 12.500 call
3 Best Stocks to Buy for Remarkable Earnings Acceleration
See More Headlines
Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:AXGN
Employees
426
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.67
High Stock Price Target
$12.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+37.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-21,720,000.00
Pretax Margin
-13.66%

Debt

Sales & Book Value

Annual Sales
$159.01 million
Book Value
$2.22 per share

Miscellaneous

Free Float
40,091,000
Market Cap
$335.74 million
Optionable
Optionable
Beta
1.07
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Ms. Karen ZaderejMs. Karen Zaderej (Age 62)
    Chairman, President & CEO
    Comp: $852.18k
  • Mr. Michael Donovan (Age 59)
    Vice President of Operations
    Comp: $406.02k
  • Mr. Angelo G. Scopelianos Ph.D. (Age 68)
    Chief Research & Development Officer
    Comp: $540.91k
  • Mr. Harold D. Tamayo
    Vice President of Finance & Investor Relations
  • Mr. Marc A. Began (Age 56)
    Executive VP, General Counsel & Chief Compliance Officer
  • Ms. Doris Quackenbush
    Vice President of Sales
  • Mr. Jens Schroeder Kemp
    Chief Marketing Officer
  • Mr. Erick DeVinney (Age 48)
    Chief Innovation Officer
  • Dr. Ivica Ducic M.D.
    Ph.D., Chief Medical Officer

AXGN Stock Analysis - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings
or view top-rated stocks.

What is AxoGen's stock price target for 2024?

3 equities research analysts have issued 12 month target prices for AxoGen's stock. Their AXGN share price targets range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 37.3% from the stock's current price.
View analysts price targets for AXGN
or view top-rated stocks among Wall Street analysts.

How have AXGN shares performed in 2024?

AxoGen's stock was trading at $6.83 at the beginning of the year. Since then, AXGN shares have increased by 13.8% and is now trading at $7.77.
View the best growth stocks for 2024 here
.

Are investors shorting AxoGen?

AxoGen saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,700,000 shares, an increase of 21.4% from the February 29th total of 1,400,000 shares. Based on an average daily volume of 427,600 shares, the days-to-cover ratio is currently 4.0 days. Currently, 4.2% of the shares of the stock are sold short.
View AxoGen's Short Interest
.

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AXGN earnings forecast
.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) released its earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.05. The medical equipment provider earned $31.20 million during the quarter, compared to the consensus estimate of $34.65 million. AxoGen had a negative trailing twelve-month return on equity of 22.38% and a negative net margin of 13.66%. During the same period in the previous year, the business earned ($0.04) earnings per share.

What ETF holds AxoGen's stock?

iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $177.0 million-$181.0 million, compared to the consensus revenue estimate of $178.9 million.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.73%), Vanguard Group Inc. (5.71%), Perceptive Advisors LLC (1.88%), Dimensional Fund Advisors LP (1.35%), Goldman Sachs Group Inc. (1.18%) and Goldman Sachs Group Inc. (1.18%). Insiders that own company stock include Amy Mcbride Wendell, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXGN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners